Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins
Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our key publication on the efficacy and safety of obicetrapib in patients with HeFH on maximally tolerated statins published in Nature Medicine. Well done, Stephen Nicholls.
Obicetrapib reduced LDL-C by ~ 36%, resulting in more patients achieving risk-based LDL-C goals and reduced Lp (a) meaningfully.
The ultimate test of this novel approach, CETPi, will come from PREVAIL.
Why it matters….. As we have shown (Hu et al., Circulation) HeFH occurs in 1:311 people globally. Our FHSC (Lancet 2021) showed globally the average age of diagnosis is 44 years, with less than 2% adults identified before the age of 18. This means that at detection, because of missed years of cholesterol exposure, 17% already have cardiovascular disease. Hence, we need to claw those years back with combination therapies. Only 2% of patients were at goal in the FHSC 2021 paper globally; we need effective, affordable treatments.
With obicetrapib expected in 2026 in Europe, we will have another tool in our arsenal to manage patients with HeFH.”
Title: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Authors: Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie L. Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael Szarek, Violeta Balinskaite, Michael H. Davidson
Read the Full Article on Nature Medicine
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event